These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879 [No Abstract] [Full Text] [Related]
8. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply. Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826 [No Abstract] [Full Text] [Related]
9. Azacitine (vidaza) for myelodysplastic syndrome. Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015 [TBL] [Abstract][Full Text] [Related]
10. Azacytidine induced localized Sweets syndrome in Myelodysplastic syndrome. Dev T; Dudani P; Bhari N Dermatol Ther; 2021 Mar; 34(2):e14754. PubMed ID: 33406304 [No Abstract] [Full Text] [Related]
11. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Prebet T; Fenaux P; Vey N; Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503 [No Abstract] [Full Text] [Related]
12. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine]. Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875 [TBL] [Abstract][Full Text] [Related]
14. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy. Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829 [No Abstract] [Full Text] [Related]
16. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]. Takahashi Y; Kimura S; Okano M Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323 [No Abstract] [Full Text] [Related]
17. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489 [No Abstract] [Full Text] [Related]
18. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971 [No Abstract] [Full Text] [Related]
19. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703 [No Abstract] [Full Text] [Related]
20. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268 [No Abstract] [Full Text] [Related] [Next] [New Search]